SCHEMBL21813347

SCHEMBL21813347

COC(=O)c1csc2c(C(F)(F)F)cc(=O)[nH]c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.52
▸ MET P08581 1/20 0.52
▸ GSK3B P49841 1/20 0.52
▸ LIMK1 P53667 1/20 0.52
▸ DYRK1A Q13627 1/20 0.52
▸ CLK4 Q9HAZ1 1/20 0.52
▸ DYRK1B Q9Y463 1/20 0.52
▸ KDM4E B2RXH2 4/20 0.46
▸ MAPT P10636 4/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ PABPC1 P11940 1/20 0.46
▸ CRHBP P24387 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46
▸ CFTR P13569 5/20 0.40
▸ CYP1A2 P05177 1/20 0.37
▸ NOTUM Q6P988 2/20 0.36
▸ GAA P10253 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ SPR P35270 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21813713 0.81 CHEK1 (0.57) CHEK1METGSK3BLIMK1DYRK1A
SCHEMBL12667302 0.78 CHEK1 (0.55) CHEK1METGSK3BLIMK1DYRK1A
SCHEMBL21813977 0.76 NGFR (0.54) CHEK1METGSK3BLIMK1DYRK1A
SCHEMBL12668951 0.75 CHEK1 (0.51) CHEK1METGSK3BLIMK1DYRK1A
SCHEMBL21813873 0.75 CHEK1 (0.45) CHEK1METGSK3BLIMK1DYRK1A
SCHEMBL21813486 0.75 CHEK1 (0.51) CHEK1METGSK3BLIMK1DYRK1A
SCHEMBL12668956 0.73 GSK3B (0.48) CHEK1METGSK3BLIMK1DYRK1A
SCHEMBL12668261 0.72 CHEK1 (0.44) CHEK1METGSK3BLIMK1DYRK1A
SCHEMBL20606230 0.71 CFTR (0.48) MAPTCFTRNOTUM
SCHEMBL12667317 0.71 GSK3B (0.46) CHEK1METGSK3BLIMK1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113423711-B Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof 建新公司 2024-03-15 — — CN disclosed
CN-113423711-A Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof 建新公司 2021-09-21 — — CN disclosed
US-20200102324-A1 UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE GENZYME CORPORATION 2020-04-02 — — US disclosed
US-20200102324-A1 UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE GENZYME CORPORATION 2020-04-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102324-A1 UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE MAN2B1, GAA, GBA1 CHEK1 4049/4885MET 4727/4885GSK3B 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback